Our Research
Discover our recent findings, catch up with news, and review in-depth resources.
Case Studies
Seeing What Immunoassays Can’t: An Ultra-Sensitive Nano-LC-MS/MS Platform for STAT6 Quantitation
Resolian developed a hybrid immunocapture nano-LC-MS/MS assay to quantify STAT6, a translational biomarker for RNA-degrading therapeutics, across human tissue types.
Case Studies
Simple by Design: A Validated 2-in-1 Assay for Acalabrutinib and Its Active Metabolite ACP-5862
Resolian developed and validated a simple, high-throughput HPLC-MS/MS method for simultaneous quantitation of acalabrutinib and its active metabolite ACP-5862 in human plasma, achieving an LLOQ of 1.00 ng/mL with a 20-minute extraction and no carryover.
Case Studies
A New Sensitivity Benchmark: Ultra-Sensitive Hybrid LC-MS/MS for siRNA Quantitation in Human Plasma
Resolian developed the first hybrid LC-MS/MS method to achieve 50 pg/mL sensitivity for a duplex siRNA and its N-1 metabolite in human plasma, setting a new benchmark for regulated siRNA bioanalysis.
Blog
Strategies for ADC Bioanalysis: Building for Complexity, Designing for the Future
Resolian’s Andy Xue on what makes ADC bioanalysis uniquely demanding, and how the team builds scalable, drug-tolerant methods across ADCs, PDCs, and AOCs.
Blog
LC-MS for Protein Biomarkers: Precision Where Immunoassays Fall Short
Resolian’s Ashley Phillips on why LC-MS outperforms immunoassays for protein biomarkers, from isoform differentiation to drug-tolerant assay design.
Case Studies
Faster, Simpler Oligonucleotide Quantitation: An Extraction-Free qPCR Workflow for Tissue and Plasma
Resolian developed an extraction-free, direct-to-qPCR workflow that accurately quantifies therapeutic oligonucleotides across plasma and multiple tissue types using a single calibration curve, reducing hands-on time and cost without compromising performance.
